Ioversol
Clinical data
Trade namesOptiray
AHFS/Drugs.comMultum Consumer Information
Pregnancy
category
  • AU: B1
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein bindingLow
MetabolismNone
Elimination half-life90 min
ExcretionKidneys
Identifiers
  • 1-N,3-N-bis(2,3-dihydroxypropyl)-5-[2-hydroxy-N-(2-hydroxyethyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.118.911 Edit this at Wikidata
Chemical and physical data
FormulaC18H24I3N3O9
Molar mass807.115 g·mol−1
3D model (JSmol)
  • C(CO)N(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)CO
  • InChI=1S/C18H24I3N3O9/c19-13-11(17(32)22-3-8(29)5-26)14(20)16(24(1-2-25)10(31)7-28)15(21)12(13)18(33)23-4-9(30)6-27/h8-9,25-30H,1-7H2,(H,22,32)(H,23,33) ☒N
  • Key:AMDBBAQNWSUWGN-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Ioversol (INN; trade name Optiray) is an organoiodine compound that is used as a contrast medium. It features both a high iodine content, as well as several hydrophilic groups. It is used in clinical diagnostics including arthrography, angiocardiography and urography.[2][3][4]

References

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  2. ^ "Drug Information Portal - U.S. National Library of Medicine - Quick Access to Quality Drug Information". druginfo.nlm.nih.gov. Retrieved 9 January 2021.
  3. ^ "Optiray (ioversol) dosing, indications, interactions, adverse effects, and more". reference.medscape.com. Retrieved 9 January 2021.
  4. ^ Chen Y, Huang X, Huang S, Matchett M (17 February 2011). "13. Fast-in-process method for the determination ioversol and related polar compounds by hydrophilic interactive chromatography". In Wang PG, He W (eds.). Hydrophilic Interaction Liquid Chromatography (HILIC) and Advanced Applications. CRC Press. p. 295-30. ISBN 978-1-4398-0753-8.
Categories